AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A therapeutic agent for a hormone-dependent cancer, which comprises:

(a) a steroid-sulfatase inhibitor; and

(b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval.

Claim 2 (currently amended): A method for treating a hormone-dependent cancer, which comprises:

administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval.

Claim 3 (currently amended): A steroid-sulfatase inhibitor, which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval.

Claim 4 (currently amended): A kit for treating a hormone-dependent cancer, which comprises:

a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy.

Claim 5 (currently amended): A pharmaceutical composition, which comprises:

(a) a steroid-sulfatase inhibitor; and

(b) an agent for hormone therapy and/or an agent for chemotherapy.

Claim 6 (canceled).

Claim 7 (currently amended): The therapeutic agent for a hormone-dependent cancer according to Claim 1, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, a compound represented by Formula (I), Formula (IA), or Formula (IB), or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



(I)

[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R^1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or $-NR^3R^4$ (wherein R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R^3 and R^4 are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and $-O-R^2$ represents a monocyclic alcohol residue or a polycyclic alcohol residue],



(IA)

(wherein $-O-R^2$, R^3, and R^4 have the same meanings as defined above, respectively), and



(IB)

[wherein R^3 and R^4 have the same meanings as defined above, respectively; R^5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, $-NR^6R^7$ (wherein R^6 and R^7 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), $-OR^8$ (wherein R^8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or $-SR^{8A}$ (wherein R^{8A} has the same meaning as R^8 defined above)].

Claim 8 (currently amended): The method for treating a hormone-dependent cancer according to Claim 2, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) ~~described in Claim 7~~ or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



(I)

[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R^1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or $-NR^3R^4$ (wherein R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R^3 and R^4 are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and $-O-R^2$ represents a monocyclic alcohol residue or a polycyclic alcohol residue],



(IA)

(wherein $-O-R^2$, R^3, and R^4 have the same meanings as defined above, respectively), and



(IB)

[wherein R^3 and R^4 have the same meanings as defined above, respectively; R^5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, $-NR^6R^7$ (wherein R^6 and R^7 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), $-OR^8$ (wherein R^8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or $-SR^{8A}$ (wherein R^{8A} has the same meaning as R^8 defined above)].

Claim 9 (currently amended): The steroid-sulfatase inhibitor according to Claim 3, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) ~~described in Claim 7~~ or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



(I)

[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R^1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or $-NR^3R^4$ (wherein R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R^3 and R^4 are combined together with the adjacent nitrogen

atom thereto to form a substituted or unsubstituted heterocyclic group); and -O-R^2 represents a monocyclic alcohol residue or a polycyclic alcohol residue],



(IA)

(wherein -O-R^2, R^3, and R^4 have the same meanings as defined above, respectively), and



(IB)

[wherein R^3 and R^4 have the same meanings as defined above, respectively; R^5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, -NR^6R^7 (wherein R^6 and R^7 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), -OR^8 (wherein R^8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or -SR^{8A} (wherein R^{8A} has the same meaning as R^8 defined above)].

Claim 10 (currently amended): The kit for treating according to Claim 4, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) ~~described in Claim 7~~ or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



(I)

[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R^1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or $-NR^3R^4$ (wherein R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R^3 and R^4 are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and $-O-R^2$ represents a monocyclic alcohol residue or a polycyclic alcohol residue],



(IA)

(wherein $-O-R^2$, R^3, and R^4 have the same meanings as defined above, respectively), and



[wherein R^3 and R^4 have the same meanings as defined above, respectively; R^5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, $-NR^6R^7$ (wherein R^6 and R^7 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), $-OR^8$ (wherein R^8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or $-SR^{8A}$ (wherein R^{8A} has the same meaning as R^8 defined above)].

Claim 11 (currently amended): The pharmaceutical composition according to Claim 5, wherein the steroid-sulfatase inhibitor is a composition comprising, as an active ingredient, the compound represented by Formula (I), Formula (IA), or Formula (IB) ~~described in Claim 7~~ or any of respective pharmaceutically acceptable salts thereof, wherein Formula (I), Formula (IA), and Formula (IB) are:



(I)

[wherein X represents a phosphorus atom or a sulfur atom, and when X is a phosphorus atom, Y is hydroxy, and when X is a sulfur atom, Y is oxo; R^1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or $-NR^3R^4$ (wherein R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, or substituted or unsubstituted aryl, or R^3 and R^4 are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group); and $-O-R^2$ represents a monocyclic alcohol residue or a polycyclic alcohol residue],



(IA)

(wherein $-O-R^2$, R^3, and R^4 have the same meanings as defined above, respectively), and



(IB)

[wherein R^3 and R^4 have the same meanings as defined above, respectively; R^5 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, $-NR^6R^7$ (wherein R^6 and R^7 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), $-OR^8$ (wherein R^8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or $-SR^{8A}$ (wherein R^{8A} has the same meaning as R^8 defined above)].

Claims 12-24 (canceled).

Claim 25 (currently amended): The therapeutic agent for a hormone-dependent cancer according to Claim 1, ~~7, 13, or 19,~~ wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a luteinizing hormone-releasing hormone (LH-RH) agonist.

Claim 26 (currently amended): The method for treating a hormone-dependent cancer according to Claim 2, ~~8, 14, or 20,~~ wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 27 (currently amended): The steroid-sulfatase inhibitor according to Claim 3, ~~9, 15, or 21,~~ wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 28 (currently amended): The kit for treating according to Claim 4, ~~10, 16, or 22,~~ wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 29 (currently amended): The pharmaceutical composition according to Claim 5, ~~11, 17, or 23,~~ wherein the agent for hormone therapy is one or more selected from the group consisting of an antiestrogen agent, an aromatase inhibitor, an antiandrogen agent, a preparation comprising progesterone, and a preparation comprising a LH-RH agonist.

Claim 30 (canceled).

Claim 31 (currently amended): The therapeutic agent for a hormone-dependent cancer according to Claim 1, ~~7, 13, or 19,~~ wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 32 (currently amended): The method for treating a hormone-dependent cancer according to Claim 2, ~~8, 14, or 20,~~ wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 33 (currently amended): The steroid-sulfatase inhibitor according to Claim 3, ~~9, 15, or 21,~~ wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 34 (currently amended): The kit for treating according to Claim 4, ~~10, 16, or 22,~~ wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 35 (currently amended): The pharmaceutical composition according to Claim 5, ~~11, 17, or 23,~~ wherein the agent for hormone therapy is an antiestrogen agent and/or an aromatase inhibitor.

Claim 36 (canceled).